Improved Outcomes for Patients Treated With Lantus(R) and Apidra(R) Regimen Compared With Sliding Scale Insulin
PARIS, FRANCE–(Marketwire – 06/25/10) – Sanofi-aventis (EURONEXT: SAN) (NYSE: SNY – News ) announced today that results from the RA ndomized Study of B asal B olus I nsulin T herapy in the Inpatient Management of Patients with Type 2 Diabetes Undergoing General Surgery (RABBIT-2 Surgery) found that treatment with a basal-bolus regimen that included Lantus (insulin glargine [rDNA origin …